#None #AIxMed #PathNet #AIxURO

AIxMed and PathNet Partnership: Enhancing Digital Pathology

In an exciting development for the world of diagnostic medicine, AIxMed, a pioneer in AI diagnostics for urine cytology, has struck a strategic partnership with PathNet, a prominent player in the diagnostic laboratory sector. Announced on November 3, 2025, this collaboration is set to significantly enhance PathNet's digital pathology platform. By integrating AIxMed's cutting-edge AIxURO™ technology, the partnership aims to enrich the existing diagnostic tools within PathNet’s laboratory ecosystem, emphasizing improved patient care and diagnostic efficiency.

Integration of AIxURO Technology

The AIxURO™ solution, developed by AIxMed, is tailor-made for the analysis of non-invasive urine cytology specimens. Its primary ambition is to elevate both the accuracy of diagnoses and the operational efficiency in assessing the presence of bladder cancer. This sophisticated software is adept at identifying suspicious and atypical cells from urine samples by employing The Paris System (TPS) for Reporting Urinary Cytology.

The attributes of the AIxURO™ technology are designed to facilitate clinical decision-making, potentially lessening the necessity for invasive procedures such as cystoscopies. In doing so, it promotes higher patient compliance and introduces a more cost-effective approach to healthcare delivery.

Leadership Insights

The executives from both companies have expressed optimism regarding this alliance. Jason Camilletti, CEO of PathNet, highlighted, "We are pleased to partner with AIxMed and augment our portfolio with their expertise in urine cytology diagnostics. This partnership is a testament to our unwavering commitment to patient care, as it integrates critical capabilities that address the needs of our diverse clientele and enhance diagnostic pathways."

Similarly, Samuel Chen, CEO of AIxMed, remarked, "We recognize PathNet as a leader in the arena of urine cytology diagnostics. We are thrilled to supply a tested and integrated solution within their operations, enabling PathNet to prioritize their cases, enhance quality control, and boost operational efficiency."

About the Companies

AIxMed was founded in 2018 and is at the forefront of revolutionizing cancer diagnosis through its advanced computational cytology platform. The company specializes in rapidly digitizing 3D cytology samples, extracting valuable clinical insights, and enhancing patient care protocols. Their flagship application, AIxURO™, currently serves as a Research Use Only (RUO) tool, specifically aiding in bladder cancer diagnosis following The Paris System protocols.

PathNet, on the other hand, is committed to modernizing pathology by employing digital and business solutions that enhance patient outcomes. They leverage the latest technology to ensure superior care, integrating solutions across clinical workflows that exceed mere laboratory processes. PathNet aims for increased efficiency, faster tissue processing, and improved turnaround times, ultimately delivering personalized treatment plans for patients.

For more detailed insights or to schedule a demonstration of AIxMed and PathNet's solutions, interested clients are encouraged to visit PathNetLab.com or AIxMed.com. Both companies are setting a new standard for diagnostic excellence in the healthcare landscape.